DoD Prostate Cancer, Translational Science Award

The summary for the DoD Prostate Cancer, Translational Science Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Prostate Cancer, Translational Science Award: The FY20 PCRP Translational Science Award (TSA) mechanism supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the FY20 PCRP Overarching Challenges. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician's firsthand knowledge of patient care. Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside, but can include a reciprocal flow of ideas and information between basic science and clinical science. This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:• Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts. The TSA is not intended to support initial mechanistic studies of a new target.• Late-stage preclinical work leading to/preparing for a clinical trial, e.g., an Investigational New Drug (IND) application submission• Correlative studies that are associated with an open/ongoing or completed clinical trial• Projects that develop endpoints for clinical trialsPreliminary data to support the feasibility of the research hypotheses and research approaches are required. The inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged.As the ultimate goal of translational research is to move a concept or observation forward into clinical application, applications must include a detailed transition plan that articulates thepathway to moving the project's findings to the next phase of development after successfulcompletion of the award and how the PI will continue advancing the research toward making aclinical impact, even if clinical impact is not an immediate outcome.Research involving human subjects is permitted under this funding opportunity; however clinical trials are not allowed. Correlative studies associated with an existing clinical trial are particularly encouraged, provided they are determined to be no greater than minimal risk by the Institutional Review Board (IRB) of record and the U.S. Army Medical Research and Development Command (USAMRDC), Office of Research Protections (ORP), Human Research Protection Office (HRPO).Investigators seeking funding for a clinical trial are encouraged to consider submitting an application to the FY20 PCRP Clinical Trial Award (Funding Opportunity Number: W81XWH- 20-PCRP-CTA).Partnering PI Option: The FY20 PCRP TSA encourages applications that include meaningful and productive collaborations between investigators. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application; collaborations between basic science and clinical researchers are highly encouraged. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. If recommended for funding, each PI will be named to an individual award within the recipient organization. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.Investigators whose studies require the use of retrospectively collected human anatomical substances or correlated data are strongly encouraged to consider utilizing the PCRP-funded Prostate Cancer Biorepository Network (PCBN) (http://prostatebiorepository.org/) and/or the North Carolina – Louisiana Prostate Cancer Project (PCaP) (https://pcap.bioinf.unc.edu).Investigators considering use of these or other resources are highly encouraged to provide a letter of support indicating access to and the availability of the desired resources to support the study.A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/ Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY20 PCRP priorities.The types of awards made under the Program Announcement will be assistance agreements. An assistance agreement is appropriate when the Federal Government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. Government. An assistance agreement can take the form ofa grant or cooperative agreement. The level of involvement on the part of the Department of Defense (DoD) during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement.Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.The anticipated direct costs budgeted for the entire period of performance for an FY20 PCRP Translational Science Award will not exceed $1M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards will be made no later than September 30, 2021. For additional information refer toSection II.F.1, Federal Award Notices.